{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '135', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '3.', 'The following components are to be used to assess the relationship between the', \"Sponsor's product and the AE; the greater the correlation with the components\", 'and their respective elements (in number and/or intensity), the more likely the', \"Sponsor's product caused the AE:\", '- Exposure: Is there evidence that the participant was actually exposed to the', \"Sponsor's product such as: reliable history, acceptable compliance assessment\", '(pill count, diary, etc.), expected pharmacologic effect, or measurement of', 'drug/metabolite in bodily specimen?', '-', 'Time Course: Did the AE follow in a reasonable temporal sequence from', \"administration of the Sponsor's product? Is the time of onset of the AE\", 'compatible with a drug-induced effect (applies to studies with investigational', 'medicinal product)?', '- Likely Cause: Is the AE not reasonably explained by another etiology such as', 'underlying disease, other drug(s)/vaccine(s), or other host or environmental', 'factors.', '-', \"Dechallenge: Was the Sponsor's product discontinued or\", 'dose/exposure/frequency reduced?', '- If yes, did the AE resolve or improve?', '- If yes, this is a positive dechallenge.', '- If no, this is a negative dechallenge.', '-', '(Note: This criterion is not applicable if: (1) the AE resulted in death or', 'permanent disability; (2) the AE resolved/improved despite continuation of the', \"Sponsor's product; (3) the study is a single-dose drug study; or (4) Sponsor's\", 'product(s) is/are only used 1 time.)', '-', \"Rechallenge: Was the participant re-exposed to the Sponsor's product in this\", 'study?', '-', 'If yes, did the AE recur or worsen?', '- If yes, this is a positive rechallenge.', '-', 'If no, this is a negative rechallenge.', '(Note: This criterion is not applicable if: (1) the initial AE resulted in death or', \"permanent disability, or (2) the study is a single-dose drug study; or (3) Sponsor's\", 'product(s) is/are used only 1 time.)', 'NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND', \"MAY HAVE BEEN CAUSED BY THE SPONSOR'S PRODUCT, OR IF RE-EXPOSURE\", 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '136', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', \"TO THE SPONSOR'S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT\", 'RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN', 'ADVANCE BY THE SPONSOR CLINICAL DIRECTOR AS PER DOSE', 'MODIFICATION GUIDELINES IN THE PROTOCOL, AND IF REQUIRED, THE', 'INIRB/IEC.', '4.', 'Consistency with study intervention profile: Is the clinical/pathological', \"presentation of the AE consistent with previous knowledge regarding the Sponsor's\", 'product or drug class pharmacology or toxicology?', '5.', 'The assessment of relationship will be reported on the case report forms/worksheets', 'by an investigator who is a qualified physician according to his/her best clinical', 'judgment, including consideration of the above elements.', '6.', 'Use the following scale of criteria as guidance (not all criteria must be present to be', \"indicative of a Sponsor's product relationship).\", \"- Yes, there is a reasonable possibility of Sponsor's product relationship:\", \"- There is evidence of exposure to the Sponsor's product. The temporal sequence of\", \"the AE onset relative to the administration of the Sponsor's product is reasonable.\", \"The AE is more likely explained by the Sponsor's product than by another cause.\", \"- No, there is not a reasonable possibility of Sponsor's product relationship:\", \"- Participant did not receive the Sponsor's product OR temporal sequence of the\", \"AE onset relative to administration of the Sponsor's product is not reasonable OR\", \"the AE is more likely explained by another cause than the Sponsor's product.\", '(Also entered for a participant with overdose without an associated AE.)', '7.', 'For each AE/SAE, the investigator must document in the medical notes that he/she', 'has reviewed the AE/SAE and has provided an assessment of causality.', '8.', 'There may be situations in which an SAE has occurred and the investigator has', 'minimal information to include in the initial report to the Sponsor. However, it is very', 'important that the investigator always make an assessment of causality for every', 'event before the initial transmission of the SAE data to the Sponsor.', '9.', 'The investigator may change his/her opinion of causality in light of follow-up', 'information and send an SAE follow-up report with the updated causality assessment.', '10.', 'The causality assessment is 1 of the criteria used when determining regulatory', 'reporting requirements.', '11.', 'For studies in which multiple agents are administered as part of a combination', 'regimen, the investigator may attribute each AE causality to the combination regimen', 'or to a single agent of the combination. In general, causality attribution should be', 'assigned to the combination regimen (ie, to all agents in the regimen). However,', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}